Omalizumab yielded a high response rate and had an acceptable safety profile in children with chronic spontaneous urticaria (CSU), including those younger than 12 years, a meta-analysis showed.

The U.S. Food and Drug Administration has approved Xolair (omalizumab) to treat chronic idiopathic urticaria, a form of chronic hives, according to a news release. Xolair, co-developed and co-promoted ...

Please provide your email address to receive an email when new articles are posted on . Both guidelines begin with antihistamines. Guidelines in the US recommend further antihistamine use before ...

In patients with chronic spontaneous urticaria, biomarkers such as a positive chronic urticaria index and low blood histamine ...

Omalizumab demonstrates superior symptom control in CSU, with 34%-44% achieving complete control in phase 3 trials. Dupilumab, an IL-4Rα antagonist, shows efficacy in CSU, particularly for patients ...

Patients with CSU have an elevated risk of anxiety and depression, necessitating comprehensive management strategies. Research is focused on identifying biomarkers and clinical characteristics to ...

ZURICH (Reuters) - Novartis said on Tuesday it was taking its experimental medicine ligelizumab to late-stage trials after the drug showed signs of outperforming existing product Xolair in treating ...

Xolair is a branded injectable medication used to treat allergic asthma, chronic hives, and rhinosinusitis. It’s recently been approved to manage food allergies, reducing the risk of serious reactions ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Medically reviewed by Susan Bard, MD Key Takeaways Over-the-counter antihistamines are a common treatment for hives. Avoiding ...

Dupilumab enhances quality of life in chronic urticaria patients unresponsive to antihistamines. Find out how treatment can ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...